ERBB2 and urothelial carcinoma: Hussain et al. 2007 investigated the HER2 overexpression rate in advanced urothelial carcinoma patients and assessed the safety and efficacy of a regimen involving trastuzumab, carboplatin, gemcitabine, and paclitaxel.